Track topics on Twitter Track topics that are important to you
By the time a 45-year-old patient with hypertension, slurred speech, and weakness in the right arm and right leg was examined in the emergency department, his symptoms had completely disappeared. However, examination, labs, and imaging showed the case was anything but "resolved."
Original Article: Case Study: Vascular Risk Factors Reach Tipping PointNEXT ARTICLE
The United States Food and Drug Administration (FDA) has approved on October 8th 2013 Adempas® (riociguat) tablets for: (i) the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) (WHO* Group 4) after ...